Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLD200 in Children Aged 4-5 Years With ADHD
NCT06431256Phase 3Terminated
- Sponsor
- Ironshore Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Jul 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HLD200 in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Ironshore Pharmaceuticals. Primary endpoint: ADHD Rating Scale-IV Preschool Version at Day 22. Started Sep 2024; status: terminated.
02
Drugs
HLD200
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06431256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431256.